\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-focal\\ neurologic\\ examination\\.\ \(1\)\
\-\ ct\\:\\ a\\ hyperdense\\ mass\\ infiltrating\\ and\\ widening\\ the\\ splenium\\ of\\ the\\ corpus\\ callosum\\.\\ a\\ poorly\\ defined\\ subtle\\ hypodense\\ lesion\\ at\\ the\\ level\\ of\\ the\\ right\\ basal\\ ganglia\\ that\\ causes\\ leftward\\ midline\\ shift\\ and\\ mass\\ effect\\ on\\ the\\ right\\ lateral\\ ventricle\\.\ \(0\)\
\-\ mri\\:\\ a\\ poorly\\ defined\\ t2\\ hyperintense\\ lesion\\ infiltrating\\ and\\ widening\\ the\\ splenium\\ of\\ the\\ corpus\\ callosum\\ with\\ an\\ additional\\ focus\\ at\\ the\\ level\\ of\\ the\\ right\\ basal\\ ganglia\\ that\\ causes\\ leftward\\ midline\\ shift\\.\\ vasogenic\\ edema\\ in\\ the\\ right\\ posterior\\ cerebral\\ hemisphere\\.\\ the\\ mass\\ has\\ mild\\,\\ irregular\\ enhancement\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\\ with\\ gliomatosis\\ cerebri\ \(0\)\
\-\ \\â\\€\\¢\\ glioblasatoma\\ multiforme\\ \ \(0\)\
\-\ \\â\\€\\¢\\ gliomatosis\\ cerebri\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 56\\ y\\.o\\.\\ woman\\ with\\ vague\\ neurological\\ symptoms\\ such\\ as\\ headache\\ and\\ lethargy\\ that\\ were\\ increasing\\ over\\ a\\ few\\ weeks\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gliomatosis\\:\\ 0\\.09884328453109618\ \(0\)\
\-\ leftward\\:\\ 0\\.09371127094924392\ \(0\)\
\-\ splenium\\:\\ 0\\.08886994380361496\ \(0\)\
\-\ cerebri\\:\\ 0\\.0811145984693317\ \(0\)\
\-\ multiforme\\:\\ 0\\.07144418449289842\ \(0\)\
\-\ infiltrating\\:\\ 0\\.06677886552619944\ \(0\)\
\-\ glioblasatoma\\:\\ 0\\.06342099585587409\ \(0\)\
\-\ callosum\\:\\ 0\\.06308923201616093\ \(0\)\
\-\ ganglia\\:\\ 0\\.062918952050017\ \(0\)\
\-\ widening\\:\\ 0\\.061937538380570485\ \(0\)\
\-\ corpus\\:\\ 0\\.06058055018673966\ \(0\)\
\-\ poorly\\:\\ 0\\.060016223378778794\ \(0\)\
\-\ shift\\:\\ 0\\.058321503441276866\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.05636742271927654\ \(0\)\
\-\ basal\\:\\ 0\\.056050899253789546\ \(0\)\
\-\ defined\\:\\ 0\\.05180694483967644\ \(0\)\
\-\ causes\\:\\ 0\\.04786447047208362\ \(0\)\
\-\ midline\\:\\ 0\\.0475702170840075\ \(0\)\
\-\ non\\-focal\\:\\ 0\\.044968122780611235\ \(0\)\
\-\ lethargy\\:\\ 0\\.03871605193871477\ \(0\)\
\-\ level\\:\\ 0\\.03543725219635874\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.03384636373951933\ \(0\)\
\-\ vasogenic\\:\\ 0\\.03327959483410124\ \(0\)\
\-\ vague\\:\\ 0\\.033064825315038786\ \(0\)\
\-\ hypodense\\:\\ 0\\.032754234150540885\ \(0\)\
\-\ 56\\:\\ 0\\.03235993029086467\ \(0\)\
\-\ that\\:\\ 0\\.03185569917752856\ \(0\)\
\-\ hemisphere\\:\\ 0\\.03129216046986989\ \(0\)\
\-\ hyperdense\\:\\ 0\\.030735421882708596\ \(0\)\
\-\ subtle\\:\\ 0\\.02823862802694061\ \(0\)\
\-\ few\\:\\ 0\\.027666943340938832\ \(0\)\
\-\ focus\\:\\ 0\\.027617155982344776\ \(0\)\
\-\ neurological\\:\\ 0\\.026600896485969378\ \(0\)\
\-\ right\\:\\ 0\\.02594623623339329\ \(0\)\
\-\ neurologic\\:\\ 0\\.02567262123601448\ \(0\)\
\-\ mass\\:\\ 0\\.02565023756001938\ \(0\)\
\-\ hyperintense\\:\\ 0\\.025522735718727842\ \(0\)\
\-\ increasing\\:\\ 0\\.025196492409530296\ \(0\)\
\-\ lesion\\:\\ 0\\.02504396008633748\ \(0\)\
\-\ additional\\:\\ 0\\.02465069564136689\ \(0\)\
\-\ irregular\\:\\ 0\\.024520479514434385\ \(0\)\
\-\ ventricle\\:\\ 0\\.023038779263154157\ \(0\)\
\-\ sclerosis\\:\\ 0\\.022081404557024065\ \(0\)\
\-\ effect\\:\\ 0\\.021766606137188813\ \(0\)\
\-\ cerebral\\:\\ 0\\.021298176271683966\ \(0\)\
\-\ headache\\:\\ 0\\.02111500314795538\ \(0\)\
\-\ such\\:\\ 0\\.01921822150964642\ \(0\)\
\-\ examination\\:\\ 0\\.019110957089745074\ \(0\)\
\-\ y\\.o\\:\\ 0\\.017743736925084175\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0175697743481258\ \(0\)\
\-\ weeks\\:\\ 0\\.017448041416555024\ \(0\)\
\-\ t2\\:\\ 0\\.01739991919964282\ \(0\)\
\-\ edema\\:\\ 0\\.017387938772886986\ \(0\)\
\-\ at\\:\\ 0\\.01665846263067098\ \(0\)\
\-\ enhancement\\:\\ 0\\.016478336446928317\ \(0\)\
\-\ \\:\\:\\ 0\\.016262946992671442\ \(0\)\
\-\ mild\\:\\ 0\\.016188873769288757\ \(0\)\
\-\ over\\:\\ 0\\.015652104965035704\ \(0\)\
\-\ metastatic\\:\\ 0\\.015475607220259643\ \(0\)\
\-\ symptoms\\:\\ 0\\.015321276812216829\ \(0\)\
\-\ woman\\:\\ 0\\.014200740629416593\ \(0\)\
\-\ posterior\\:\\ 0\\.014170061501456466\ \(0\)\
\-\ mri\\:\\ 0\\.01412428672600446\ \(0\)\
\-\ were\\:\\ 0\\.013958894508560585\ \(0\)\
\-\ lateral\\:\\ 0\\.013285381623198204\ \(0\)\
\-\ multiple\\:\\ 0\\.01294824462934726\ \(0\)\
\-\ has\\:\\ 0\\.011544604104275382\ \(0\)\
\-\ a\\:\\ 0\\.011412943937225936\ \(0\)\
\-\ the\\:\\ 0\\.010940590875826502\ \(0\)\
\-\ disease\\:\\ 0\\.01004847151953744\ \(0\)\
\-\ as\\:\\ 0\\.009299118747439768\ \(0\)\
\-\ ct\\:\\ 0\\.00859930685893556\ \(0\)\
\-\ an\\:\\ 0\\.008501186073990863\ \(0\)\
\-\ on\\:\\ 0\\.0052078490098232235\ \(0\)\
\-\ and\\:\\ 0\\.005180115272869596\ \(0\)\
\-\ of\\:\\ 0\\.003352627361093192\ \(0\)\
\-\ in\\:\\ 0\\.003031634749210467\ \(0\)\
\-\ with\\:\\ 0\\.002525269987551577\ \(0\)\
\-\ \\.\\:\\ 0\\.0020431387681925915\ \(0\)\
\-\ \\,\\:\\ 0\\.0019475544281819237\ \(0\)\
